Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–60.

Article  CAS  PubMed  Google Scholar 

Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA. SEER Cancer Statistics Review, 1975-2017, vol. 2020. Bethesda, MD: National Cancer Institute. Available from: https://seer.cancer.gov/csr/1975_2017/. Accessed 30 Jan 2023.

The Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute. Cancer Stat Facts: Leukemia-Chronic Lymphocytic Leukemia 2022. Available from: https://seer.cancer.gov/statfacts/html/clyl.html. Accessed 30 Jan 2023.

International CLL-IPI Working Group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17(6):779–90.

Article  Google Scholar 

Kajuter H, Wellmann I, Khil L, Jockel KH, Zhang C, Fink AM, et al. Survival of patients with chronic lymphocytic leukemia before and after the introduction of chemoimmunotherapy in Germany. Blood Cancer J. 2021;11(10):174.

Article  PubMed  PubMed Central  Google Scholar 

Burger JA. Treatment of chronic lymphocytic leukemia. N Engl J Med. 2020;383(5):460–73.

Article  CAS  PubMed  Google Scholar 

Hallek M, Al-Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol. 2021;96(12):1679–705.

Article  PubMed  Google Scholar 

Hilal T, Prasad V. Eliminating MRD - FDA approval of blinatumomab for B-ALL in complete remission. Nat Rev Clin Oncol. 2018;15(12):727–8.

Article  CAS  PubMed  Google Scholar 

Berry DA, Zhou S, Higley H, Mukundan L, Fu S, Reaman GH, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3(7):e170580.

Article  PubMed  PubMed Central  Google Scholar 

Saad ED, Buyse M. Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents. Ann Oncol. 2016;27(3):373–8.

Article  CAS  PubMed  Google Scholar 

Korn EL, Freidlin B, Abrams JS. Overall survival as the outcome for randomized clinical trials with effective subsequent therapies. J Clin Oncol. 2011;29(17):2439–42.

Article  PubMed  PubMed Central  Google Scholar 

Research CfDEa, Research CfBEa. Hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment. Guidance for Industry 2020. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/hematologic-malignancies-regulatory-considerations-use-minimal-residual-disease-development-drug-and. Accessed 31 Jan 2023.

Agency EM. Use of minimal residue disease as an endpoint in chronic lymphocytic leukemia studies - scientific guideline 2014. Available from: https://www.ema.europa.eu/en/use-minimal-residue-disease-endpoint-chronic-lymphocytic-leukaemia-studies-scientific-guideline. Accessed 31 Jan 2023.

Yang S, Kay NE, Shi M, Ossenkoppele G, Walter RB, Gale RP. Measurable residual disease testing in chronic lymphocytic leukaemia: hype, hope neither or both? Leukemia. 2021;35. England:3364–70.

Article  PubMed  Google Scholar 

Kittai AS, Woyach JA. uMRD: “the” endpoint or “an” endpoint for CLL? Blood. 2022;140. United States:797–8.

Article  CAS  PubMed  Google Scholar 

Yang S, Kay NE, Shi M, Hanson CA, Gale RP. Is unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory approvals and therapy decisions in chronic lymphocytic leukaemia (CLL)? Leukemia. 2022;36(11):2743–7.

Article  PubMed  Google Scholar 

Kater Arnon P, Owen C, Moreno C, Follows G, Munir T, Levin M-D, et al. Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evidence. 2022;1(7):EVIDoa2200006.

Google Scholar 

Wang XV, Hanson CA, Tschumper RC, Lesnick CE, Braggio E, Paietta EM, et al. Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. Blood. 2021;138(26):2810–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Strati P, Keating MJ, O’Brien SM, Burger J, Ferrajoli A, Jain N, et al. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood. 2014;123(24):3727–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Soumerai JD, Mato AR, Dogan A, Seshan VE, Joffe E, Flaherty K, et al. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2021;8(12):e879–e90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thompson PA, Tam CS, O’Brien SM, Wierda WG, Stingo F, Plunkett W, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127(3):303–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, et al. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia. 2016;30(4):929–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rawstron AC, Böttcher S, Letestu R, Villamor N, Fazi C, Kartsios H, et al. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia. 2013;27(1):142–9.

Article  CAS  PubMed  Google Scholar 

Uhrmacher S, Erdfelder F, Kreuzer KA. Flow cytometry and polymerase chain reaction-based analyses of minimal residual disease in chronic lymphocytic leukemia. Adv Hematol. 2010;2010:272517.

Ching T, Duncan ME, Newman-Eerkes T, McWhorter MME, Tracy JM, Steen MS, et al. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma. BMC Cancer. 2020;20(1):612.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rodríguez-Vicente AE, Bikos V, Hernández-Sánchez M, Malcikova J, Hernández-Rivas JM, Pospisilova S. Next-generation sequencing in chronic lymphocytic leukemia: recent findings and new horizons. Oncotarget. 2017;8(41):71234–48.

Article  PubMed  PubMed Central  Google Scholar 

Raponi S, Della Starza I, De Propris MS, Del Giudice I, Mauro FR, Marinelli M, et al. Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR. Br J Haematol. 2014;166(3):360–8.

Article  CAS  PubMed  Google Scholar 

Böttcher S, Stilgenbauer S, Busch R, Brüggemann M, Raff T, Pott C, et al. Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis. Leukemia. 2009;23(11):2007–17.

Article  PubMed  Google Scholar 

Itälä M, Huhtinen AR, Juvonen V, Kairisto V, Pelliniemi TT, Penttilä TL, et al. Stem cell transplantation in poor-risk chronic lymphocytic leukemia: assessment of post-transplant minimal residual disease using four- and six-color flow cytometry and allele-specific RQ-PCR. Eur J Haematol. 2008;81(2):100–6.

Article  PubMed  Google Scholar 

Thompson PA, Srivastava J, Peterson C, Strati P, Jorgensen JL, Hether T, et al. Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. Blood. 2019;134(22):1951–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hengeveld PJ, van der Klift MY, Kolijn PM, Davi F, Kavelaars FG, de Jonge E, et al. Detecting measurable residual disease beyond 10–4 through an IGHV leader-based NGS approach improves prognostic stratification in CLL. Blood. 2023;141(5):519–28.

Article  CAS  PubMed  Google Scholar 

Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225–36.

Article  CAS  PubMed  Google Scholar 

Al-Sawaf O, Zhang C, Lu T, Liao MZ, Panchal A, Robrecht S, et al. Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study. J Clin Oncol. 2021;39(36):4049–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gutman JA, Winters A, Kent A, Amaya M, McMahon C, Smith C, et al. Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia. Haematologica. 2023. https://doi.org/10.3324/haematol.2023.282681.

Chauhan PS, Shiang A, Alahi I, Sundby RT, Feng W, Gungoren B, et al. Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients. NPJ Precis Oncol. 2023;7(1):6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lew TE, Anderson MA, Lin VS, Handunnetti SM, Came NA, Blombery P, et al. Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months. Blood Adv. 2020;4(1):165–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164–74.

Article  CAS  PubMed  Google Scholar 

Böttcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012;30(9):980–8.

Article  PubMed  Google Scholar 

Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101–10.